BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Bonaventura A, Montecucco F. Sofosbuvir/velpatasvir: A promising combination. World J Hepatol 2016; 8(19): 785-789 [PMID: 27429714 DOI: 10.4254/wjh.v8.i19.785]
URL: https://www.wjgnet.com/1007-9327/full/v8/i19/785.htm
Number Citing Articles
1
Tarek Saadi, Johad Khoury. Is There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies?Journal of Clinical Gastroenterology 2018; 52(4): 353 doi: 10.1097/MCG.0000000000000853
2
Johad Khoury, George Nassar, Rimma Kramsky, Tarek Saadi. Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV InfectionJournal of Gastrointestinal Cancer 2020; 51(2): 584 doi: 10.1007/s12029-019-00293-y
3
Kelli Wuerth, Tianna Magel, Brian Conway. Sofosbuvir and Velpatasvir in the Treatment of Chronic Hepatitis CFuture Virology 2019; 14(11): 715 doi: 10.2217/fvl-2019-0104
4
Ariel Bardach, Akram Hernández-Vásquez, Alfredo Palacios, María Calderón, Natalie Soto, Dario Balan, Federico Augustovski. Epidemiology, Use of resources, and Costs of Medical Management of Hepatitis C in Argentina, Colombia, Uruguay, and VenezuelaValue in Health Regional Issues 2019; 20: 180 doi: 10.1016/j.vhri.2019.06.004
5
Chayan Bhattacharjee, Maitri Singh, Debisukti Das, Sujit Chaudhuri, Aparna Mukhopadhyay. Current therapeutics against HCVVirusDisease 2021; 32(2): 228 doi: 10.1007/s13337-021-00697-0
6
Victoria Green, Marina Roytman, Haruki Komatsu. Treatment-Resistant Hepatitis C Viral Infection: A Case Report and Literature ReviewCase Reports in Hepatology 2022; 2022: 1 doi: 10.1155/2022/3556780
7
Sarah Billington, Adrian S. Ray, Laurent Salphati, Guangqing Xiao, Xiaoyan Chu, W. Griffith Humphreys, Mingxiang Liao, Caroline A. Lee, Anita Mathias, Cornelis E. C. A. Hop, Christopher Rowbottom, Raymond Evers, Yurong Lai, Edward J. Kelly, Bhagwat Prasad, Jashvant D. Unadkat. Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS ProteomicsDrug Metabolism and Disposition 2018; 46(2): 189 doi: 10.1124/dmd.117.077289
8
Carla Rizzo, Sara Amata, Ivana Pibiri, Andrea Pace, Silvestre Buscemi, Antonio Palumbo Piccionello. FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022International Journal of Molecular Sciences 2023; 24(9): 7728 doi: 10.3390/ijms24097728
9
Md. Kaderi Kibria, Md. Ahad Ali, Muhammad Yaseen, Imran Ahmad Khan, Mashooq Ahmad Bhat, Md. Ariful Islam, Rashidul Alam Mahumud, Md. Nurul Haque Mollah. Discovery of Bacterial Key Genes from 16S rRNA-Seq Profiles That Are Associated with the Complications of SARS-CoV-2 Infections and Provide Therapeutic IndicationsPharmaceuticals 2024; 17(4): 432 doi: 10.3390/ph17040432
10
Ya-Chao Tao, Rong Deng, Meng-Lan Wang, Duo-Duo Lv, Man Yuan, Yong-Hong Wang, En-Qiang Chen, Hong Tang. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort studyVirology Journal 2018; 15(1) doi: 10.1186/s12985-018-1066-8
11
Federica Riccio, Sandeep K. Talapatra, Sally Oxenford, Richard Angell, Michela Mazzon, Frank Kozielski. Development and validation of RdRp Screen, a crystallization screen for viral RNA-dependent RNA polymerasesBiology Open 2019; 8(1) doi: 10.1242/bio.037663
12
Islam Shah, Wiqas Ahmad, Abdul Qadir, Iltaf Muhammad, Muhammad Islam, Mustaqeem Shah, Naeem Jan, Sadia Anjum. Efficacy and Safety of Sofosbuvir and Velpatasvir Combination for the Treatment of Chronic Hepatitis C in Patients With or Without CirrhosisCureus 2021;  doi: 10.7759/cureus.19768
13
Adarsh Singh, Riddhiman Dhar. A large-scale computational screen identifies strong potential inhibitors for disrupting SARS-CoV-2 S-protein and human ACE2 interactionJournal of Biomolecular Structure and Dynamics 2022; 40(19): 9004 doi: 10.1080/07391102.2021.1921034